<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Urate balance</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Urate balance</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Urate balance</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David B Mount, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicola Dalbeth, MBChB, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 24, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uric acid is the end product of purine metabolism. Most uric acid circulates as the urate anion, and serum urate concentrations normally approach the theoretical limit of serum urate solubility. Human tissues have a very limited ability to metabolize urate; thus, uric acid must be eliminated by the kidney and the gut to maintain urate homeostasis. Factors affecting urate production and excretion that cause hyperuricemia result in an increased risk for asymptomatic hyperuricemia and gout, and for uric acid nephrolithiasis.</p><p>The processes that influence and maintain urate balance are described here. Asymptomatic hyperuricemia, the pathogenesis of gout, and the mechanisms that underlay uric acid renal diseases, including uric acid nephrolithiasis, are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1669.html" rel="external">"Asymptomatic hyperuricemia"</a> and  <a class="medical medical_review" href="/z/d/html/1673.html" rel="external">"Pathophysiology of gout"</a> and  <a class="medical medical_review" href="/z/d/html/7379.html" rel="external">"Uric acid kidney diseases"</a> and  <a class="medical medical_review" href="/z/d/html/7378.html" rel="external">"Kidney stones in adults: Uric acid nephrolithiasis"</a>.)</p><p class="headingAnchor" id="H3140742077"><span class="h1">URIC ACID AND URATE</span><span class="headingEndMark"> — </span>Uric acid, a weak organic acid, is the end product of the metabolism of purine compounds in humans and some other primate species. With a (functional) pKa of approximately 5.75 in blood (5.35 in urine), the reaction</p><div class="formulaContainer"><div class="formula"><p>    Uric acid  &lt;—&gt;    Urate-  +  H+</p></div></div><p>is shifted far to the right at the normal arterial pH of 7.40. As a result, most uric acid, which is poorly soluble in its undissociated form, circulates as the substantially more soluble urate anion.</p><p>Urate is the end product of purine metabolism in humans because the human homolog of the mammalian uricase (urate oxidase) gene is structurally modified to an unexpressed (pseudogene) state. By contrast, the vast majority of other mammalian species have extremely low serum urate levels (approximately 1 mg/dL; 60 micromol/L) because urate in these species is converted by uricase to allantoin, a highly soluble excretory product. Normal humans have serum urate concentrations that approach the theoretical limit of urate solubility (6.8 mg/dL; 405 micromol/L) and regularly excrete urine that is supersaturated with respect to uric acid.</p><p>The typical adult male has a total body urate pool of approximately 1200 mg, approximately twice that of the normal adult female. This sex difference may be explained by an enhancement of renal urate excretion in women of childbearing age due to the effects of estrogenic compounds [<a href="#rid1">1</a>], which likely reduce the number of active renal reabsorptive urate transporters, resulting in less renal tubular uric acid reabsorption and consequently greater urate clearance [<a href="#rid2">2,3</a>]. Normally, all urate measured in the body pool is believed to be soluble urate. When insoluble urate crystal deposition occurs (in gout), body pool measurements underestimate the body urate pool. Under normal steady state conditions, daily turnover of approximately 60 percent of the urate pool is achieved by balanced production and elimination of urate.</p><p>The prevalence of hyperuricemia rose in the United States from the 1960s to the early 2000s but was stable from 2007 to 2016, as indicated by data from the National Health and Nutrition Examination Survey from 2007 to 2016, which found that hyperuricemia (defined in men in the study as a single urate determination exceeding 7 mg/dL) was present in up to 20.2 percent of adult males surveyed [<a href="#rid4">4</a>]. By contrast, the mean serum urate concentration had formerly been reported as between 5 and 6 mg/dL among healthy adult White men in the United States, and the prevalence of hyperuricemia as at least 5 to 8 percent. (See  <a class="medical medical_review" href="/z/d/html/1669.html" rel="external">"Asymptomatic hyperuricemia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">URATE PRODUCTION</span><span class="headingEndMark"> — </span>Urate is not typically ingested; the major site of urate production is the liver, where it is produced by the degradation of dietary and endogenously synthesized purine compounds. Dietary intake appears to provide a significant source of urate precursors, as a purine-free formula diet reduces urinary excretion of uric acid by approximately 40 percent [<a href="#rid5">5</a>].</p><p>Urate production (ie, purine degradation) involves the breakdown of the purine mononucleotides, guanylic acid (guanosine monophosphate, GMP), inosinic acid (inosine monophosphate, IMP), and adenylic acid (adenosine monophosphate, AMP), ultimately into the purine bases guanine and hypoxanthine. These last two compounds are then metabolized to xanthine. In the final step, which is catalyzed by the enzyme xanthine oxidase, xanthine is irreversibly oxidized to produce urate  (<a class="graphic graphic_figure graphicRef75554" href="/z/d/graphic/75554.html" rel="external">figure 1</a>).</p><p>Defects in purine metabolism can cause hyperuricemia due to overproduction of urate, although these are very uncommon in the population compared with a range of medical conditions, medications, and other factors that can also cause increased purine biosynthesis or urate production  (<a class="graphic graphic_table graphicRef80891" href="/z/d/graphic/80891.html" rel="external">table 1</a>). These rare monogenic disorders include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency</strong> – Purines can be salvaged through a pathway involving the enzyme HPRT; thus, genetic deficiency of HPRT in Lesch-Nyhan syndrome and related disorders is associated with hyperuricemia and gout, among other findings [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Lesch-Nyhan syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>5'-phosphoribosyl 1-pyrophosphate (PRPP) synthetase overactivity</strong> – The de novo synthesis of purines involves the production of PRPP from adenosine triphosphate (ATP) and ribose 5'-phosphate. This step is catalyzed by PRPP synthetase; as a result, genetic overactivity of this enzyme is also associated with hyperuricemia and gout [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucose-6-phosphatase deficiency (glycogen storage disease, type I)</strong> – ATP degradation leads to adenosine diphosphate (ADP) and AMP production, with subsequent metabolism to urate; thus, conditions associated with net degradation of ATP, such as glycogen storage disease, particularly type I, can also be associated with hyperuricemia and gout ("myogenic hyperuricemia") [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">URIC ACID DISPOSAL</span><span class="headingEndMark"> — </span>The excretion of intact urate by the gut and the kidney is required to maintain urate homeostasis because metabolism of urate is negligible in human tissues under normal physiologic circumstances, in which it is limited to minor nonspecific oxidation by peroxidases and catalases. Approximately one-third of daily urate disposal is by the gut, and two-thirds of the daily disposal of uric acid is by the kidneys.</p><p class="headingAnchor" id="H4"><span class="h2">Gastrointestinal tract</span><span class="headingEndMark"> — </span>Urate efflux into the gut lumen is an active process mediated by urate transporters, rather than being a concentration-dependent passive process, as was historically thought. The best studied of these transporters is ABCG2 (also called the breast cancer resistance protein or BCRP) [<a href="#rid9">9-11</a>].</p><p>ABCG2 is a high-capacity urate transporter encoded by the <em>ABCG2</em> gene on chromosome 4; it is expressed in intestinal epithelium and on the luminal surface of renal proximal tubule epithelial cells [<a href="#rid12">12</a>]. Intestinal tract bacteria are able to degrade urate, and this breakdown process (intestinal uricolysis) is responsible for approximately one-third of total urate disposal, which comprises nearly all the urate disposed of by extra-renal routes. Under normal conditions, urate in the gut is almost completely degraded by colonic bacteria, with little being found in the stool [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Urinary excretion</span><span class="headingEndMark"> — </span>Urinary uric acid excretion normally accounts for the remaining two-thirds of the daily uric acid disposal that is not carried out in the gut. All or nearly all urate is readily available for filtration at the glomerulus. However, renal clearance of uric acid in normal adults is only 7 to 12 percent of the filtered load, indicating that, under usual circumstances, there is net tubular reabsorption of approximately 90 percent of filtered urate. Urate handling involves glomerular filtration and urinary excretion, with separate tubular reabsorptive and secretory processes mediated by completely separate sets of transport mechanisms [<a href="#rid11">11</a>]. (See <a class="local">'Renal reabsorptive urate transport'</a> below and <a class="local">'Renal secretory urate transport'</a> below.)</p><p class="headingAnchor" id="H2557575839"><span class="h1">RENAL REABSORPTIVE URATE TRANSPORT</span><span class="headingEndMark"> — </span>Urate reabsorption by the proximal tubule requires the cooperation of several apical and basolateral transporters. Filtered urate is absorbed at the apical membrane by the urate-anion exchangers URAT1 [<a href="#rid14">14</a>] and OAT10  (<a class="graphic graphic_figure graphicRef83926 graphicRef83925" href="/z/d/graphic/83926.html" rel="external">figure 2A-B</a>) [<a href="#rid15">15,16</a>]. Both of these transporters are inhibited by uricosuric agents, including benzbromarone and <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a>. URAT1 is also inhibited by verinurad [<a href="#rid17">17,18</a>].</p><p>These transporters have the highest affinity for urate exchange with aromatic organic anions, such as nicotinate and pyrazinoate (PZA), followed by lactate, beta-hydroxybutyrate, and acetoacetate. The intracellular concentration of these monovalent anions is thus a key determinant of the activity of URAT1 and OAT10, with marked activation of urate transport when their intracellular concentration is increased [<a href="#rid15">15</a>]; this activation of urate-anion exchange by intracellular anionic substrates is referred to as "trans-activation." Similar trans-activation of urate-anion exchange can be seen in brush border membrane vesicles generated from renal cortex [<a href="#rid19">19,20</a>]. By contrast, higher concentrations of these anions can progressively compete with urate for absorption, leading eventually to "cis-inhibition." The intracellular concentrations of these anions in proximal tubular cells are largely determined by apical uptake via the Na<sup>+</sup>-dependent monocarboxylate transporters SMCT1 and SMCT2 [<a href="#rid11">11</a>], such that apical urate absorption by the proximal tubule has a secondary sodium dependency.</p><p>The various anions that participate in the SMCT1/SMCT2-URAT1/OAT10 interaction have potent anti-uricosuric effects in vivo. Increases in the plasma concentrations of these anti-uricosuric anions result in increased glomerular filtration, increased delivery to the proximal tubule, increased Na<sup>+</sup>-dependent uptake by SMCT1 or SMCT2, and increased intracellular concentration in tubular epithelial cells. The increases in intracellular activity of these anions in turn induce urate reabsorption and hyperuricemia, via "trans-stimulation" of URAT1 and OAT10 from inside the cell.</p><p>This "anti-uricosuric" physiology has several clinical correlates. For example, the increase in circulating beta-hydroxybutyrate and acetoacetate in diabetic ketoacidosis can cause initial hyperuricemia, which is lessened by treatment of the diabetic ketoacidosis with insulin [<a href="#rid21">21,22</a>]. Hyperuricemia is also a complication of a high-fat diet [<a href="#rid23">23</a>] and of starvation ketosis [<a href="#rid24">24</a>]. Increases in lactic acid, as seen in alcohol intoxication [<a href="#rid25">25</a>], can also result in hyperuricemia due to increased urate reabsorption; transient increases in lactate and/or keto acids may contribute to the association between gout and alcohol intake [<a href="#rid26">26</a>]. The effects of keto acids and lactate are not caused by their respective acidoses, given that the experimental infusion of these anions causes hyperuricemia [<a href="#rid21">21,27,28</a>].</p><p>The particularly potent interactions between nicotinate and PZA with URAT1 and OAT10 also have in vivo clinical counterparts. The treatment of hypercholesterolemia with nicotinic acid (<a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">niacin</a>) is thus frequently complicated by hyperuricemia [<a href="#rid29">29</a>], as is the treatment of tuberculosis with <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a> [<a href="#rid30">30</a>].</p><p>When uricosuric drugs are administered after <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a>, there is a marked attenuation of their uricosuric effect [<a href="#rid31">31</a>]. The "trans-activation" model of the anti-uricosuric effect of PZA, via stimulation of urate reabsorption rather than inhibition of secretion, is viewed as the likely explanation for these observations, which is inconsistent with the older four-component model [<a href="#rid31">31</a>]. Physiologic studies in reabsorptive species typically indicate a co-existence of reabsorption and secretion along the entire length of the proximal tubule.</p><p>Certain drugs can cause a reduction in serum urate levels due to uricosuric effects. For example, <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a> and <a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">fenofibrate</a> inhibit URAT1, leading to uricosuria and reduced serum urate [<a href="#rid32">32,33</a>]. Additionally, the active metabolite of <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, oxypurinol, is a substrate for URAT1, such that uricosurics such as benzbromarone and <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> can increase the renal clearance of oxypurinol [<a href="#rid34">34</a>].</p><p>Following apical reabsorption of urate by URAT1 and OAT10, urate exits proximal tubular cells via the GLUT9 urate antiporter  (<a class="graphic graphic_figure graphicRef83926 graphicRef83925" href="/z/d/graphic/83926.html" rel="external">figure 2A-B</a>), encoded by the <em>SLC2A9 </em>gene. Variation in the <em>SLC2A9</em> gene was initially identified in genome-wide association studies as a significant genetic factor in determination of serum urate levels [<a href="#rid2">2,35</a>], with no prior hints that the GLUT9 transporter played a role in urate homeostasis. The <em>SLC2</em> gene family of GLUT transporters primarily functions in glucose and fructose transport, whereas GLUT9 is a uniquely potent urate transporter with minimal if any activity as a hexose transporter [<a href="#rid36">36</a>]. Urate transport mediated by GLUT9 is sensitive to uricosurics and is electrogenic, with a marked activation of transport in membrane-depolarized cells [<a href="#rid15">15,37</a>]; the interior-negative membrane potential of proximal tubule cells favors basolateral exit of urate from the cell via GLUT9.</p><p class="headingAnchor" id="H1812600472"><span class="h1">RENAL SECRETORY URATE TRANSPORT</span><span class="headingEndMark"> — </span>Urate secretion by the proximal tubule is mediated by multiple transporters that are distinct from the reabsorptive transporters  (<a class="graphic graphic_figure graphicRef83926 graphicRef83925" href="/z/d/graphic/83926.html" rel="external">figure 2A-B</a>). Urate enters the cell from the interstitium across the basolateral membrane, via the OAT1, OAT2, and OAT3 anion exchangers. Unlike OAT10 and URAT1 at the apical membrane, OAT1 and OAT3 exchange urate with divalent anions, primarily alpha-ketoglutarate [<a href="#rid38">38,39</a>]. Basolateral Na<sup>+</sup>-dependent uptake of alpha-ketoglutarate is mediated by the NADC-3 transporter [<a href="#rid38">38,39</a>]. This uptake, by increasing the intracellular concentration of alpha-ketoglutarate, results in trans-stimulation of basolateral urate-anion exchange, analogous to the interactions at the apical membrane between monovalent anti-uricosuric anions and urate uptake. OAT2, in contrast to OAT1 and OAT3, appears to interact with monovalent anions such as pyrazinoate (PZA) [<a href="#rid40">40</a>]; the relevant endogenous anion is not known.</p><p>At the apical membrane of proximal tubular cells, urate exits the cell by secretion through two adenosine triphosphate (ATP)-driven efflux pumps, ABCG2 and ABCC4. In addition, there are two electrogenic apical urate antiporters, NPT1 and NPT4, that also contribute to urate exit during secretion [<a href="#rid41">41,42</a>]. Like basolateral exit via GLUT9, the exit of urate at the apical membrane through NPT1 and NPT4 is thought to be driven in part by the cell-negative membrane potential.</p><p class="headingAnchor" id="H2250606303"><span class="h1">REGULATION OF SERUM URATE LEVELS</span><span class="headingEndMark"> — </span>Serum urate levels can be modulated by diverse physiologic conditions and neurohumoral factors. Volume status and salt balance, in particular, have potent effects on circulating serum urate.</p><p>Experimentally, salt restriction causes significant hyperuricemia, which is reversed by salt loading [<a href="#rid11">11</a>]. For example, in hypertensive subjects, there is a 1.8 to 2.0 mg/dL difference in serum urate between salt intakes of 29 to 38 milliequivalent/day and 258 milliequivalent/day [<a href="#rid43">43</a>].</p><p>Potential neurohumoral mediators include angiotensin-II and <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, both of which can experimentally reduce the fractional excretion of urate in humans [<a href="#rid44">44</a>].</p><p>Clinically, volume depletion is associated with hyperuricemia, explaining in large part the association between diuretic use and gout [<a href="#rid45">45</a>]. The modest increase in extracellular fluid volume associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is in turn associated with an increase in fractional excretion of urate, such that a low serum urate is an important key to the diagnosis of SIADH [<a href="#rid46">46</a>].</p><p>Hyperuricemia and gout are important concomitants of the metabolic syndrome [<a href="#rid47">47</a>], suggesting a role for hyperinsulinemia and insulin signaling in regulation of renal urate transport [<a href="#rid48">48</a>]. Insulin appears to reduce renal fractional excretion of urate [<a href="#rid49">49,50</a>]. A comprehensive survey of reabsorptive and secretory urate transporters has shown that multiple urate transporters are activated by insulin [<a href="#rid51">51</a>]. It has been proposed that the anti-uricosuric effect of insulin is primarily due to the enhanced expression and activation of GLUT9, given that the high-capacity urate transporter GLUT9a is the exclusive basolateral exit pathway for reabsorbed urate from the renal proximal tubule into the blood, that insulin stimulates both GLUT9 expression and urate transport activity more than other urate transporters, and that the <em>SLC2A9</em> gene that encodes GLUT9 shows genetic interaction with urate-associated insulin-signaling loci [<a href="#rid51">51</a>]. Excess parathyroid hormone (PTH) activity also reduces urate excretion, in both primary hyperparathyroidism [<a href="#rid52">52</a>] and during pharmacologic therapy with <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> for osteoporosis [<a href="#rid53">53</a>].</p><p>Serum urate is typically depressed during gout flares compared with baseline levels, which has been postulated to occur due to cytokine-stimulated uricosuria [<a href="#rid54">54,55</a>]. The mediators and target urate transporters remain uncharacterized.</p><p class="headingAnchor" id="H6"><span class="h1">HYPERURICEMIA</span><span class="headingEndMark"> — </span>Decreased efficiency of renal uric acid excretion is responsible for most primary or secondary hyperuricemia  (<a class="graphic graphic_table graphicRef66799" href="/z/d/graphic/66799.html" rel="external">table 2</a>) [<a href="#rid56">56,57</a>]. This observation is not surprising given the complexity of renal uric acid handling and the sensitivity of the kidney to endogenous metabolites, alterations in volume status, and drugs. Volume depletion due to diuretics, for example, is a common cause of hyperuricemia. (See  <a class="medical medical_review" href="/z/d/html/2380.html" rel="external">"Diuretic-induced hyperuricemia and gout"</a>.)</p><p>It is important to appreciate, however, that "underexcretors" actually have normal rates of urinary uric acid excretion since this is required to maintain the steady state in which urate production and disposal are relatively equal (see  <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'The steady state'</a>). It is the reduced efficiency of urate excretion that obligates a higher serum urate concentration in order to achieve the necessary rate of urinary uric acid excretion.</p><p>The remaining minority of patients with hyperuricemia ostensibly overproduce urate. Disorders that cause overproduction include inherited defects in regulation of purine nucleotide synthesis, disordered adenosine triphosphate (ATP) metabolism, or disorders that result in increased rates of cell turnover [<a href="#rid6">6-8</a>]. However, even among those whose daily excretion of uric acid is higher than normal, decreased efficiency of renal uric acid excretion may also play a role [<a href="#rid57">57</a>].</p><p>Several studies provide a likely mechanistic basis for the observed role of decreased efficiency of uric acid excretion [<a href="#rid9">9,10</a>]. In some gout patients with a hyperuricemia/gout risk allele (polymorphism) for the high-capacity urate transporter ABCG2, daily excretion of uric acid in the urine was paradoxically well within the normal range and often in a range (&gt;800 mg/day) implying urate overproduction [<a href="#rid9">9</a>]. Since the gene product, Abcg2, is expressed in the gut as well as the renal proximal tubule, this paradox apparently results from the genetically determined underexcretion of urate in the gut, with consequent compensatory (but still relatively reduced) uric acid clearance at the kidney. This view was supported by the finding that patients with two risk alleles showed higher serum urate and urinary uric acid levels, implying that reduction of intestinal urate excretion directly correlated with increases in urate blood and urine burdens. Subsequent studies have indicated that subjects with a "urate-raising" allele of <em>ABCG2</em> lose a substantial component of extrarenal urate excretion [<a href="#rid58">58</a>]. Excessive daily urinary uric acid excretion thus does not unequivocally imply urate overproduction. Rather, overexcretion of urinary uric acid may result from either "extra-renal urate underexcretion" or from genuine urate overproduction. (See  <a class="medical medical_review" href="/z/d/html/1669.html" rel="external">"Asymptomatic hyperuricemia"</a>.)</p><p>Genetic variation in almost all the urate transporter genes involved in urate reabsorption and secretion has been implicated in serum urate variation; other implicated genes affect transcriptional and post-transcriptional regulation of urate transport [<a href="#rid59">59</a>]. Variation in &gt;200 genes has been implicated in serum urate variation [<a href="#rid60">60,61</a>]. Notably, the relative balance of reabsorption and secretion is a major determinant of renal excretion of uric acid and thus of serum urate. For example, loss-of-function mutations in renal secretory urate transporters, such as NPT1 [<a href="#rid62">62</a>], NPT4, and ABCC4 [<a href="#rid63">63</a>], can contribute to an increase in serum urate by reducing the relative activity of renal urate secretion. Like the variation in <em>ABCG2</em> mentioned above, genetic variation in the <em>SLC2A9</em> gene encoding GLUT9 has been found to exert a particularly significant effect on serum urate levels [<a href="#rid2">2,35</a>]. Translational studies have utilized inosine loading to characterize the role of GLUT9 in human urate physiology, demonstrating a higher fractional excretion of urate in subjects with the protective (urate-lowering) C allele of <em>SLC2A9</em> rs11942223 [<a href="#rid58">58</a>]. This indicates that the urate-lowering allele in <em>SLC2A9</em> reduces GLUT9 function in urate reabsorption within the kidney.</p><p>Diet and lifestyle, particularly alcohol intake [<a href="#rid26">26</a>], can affect serum urate and the risk of gout. For example, higher consumption of purine-rich foods, particularly meat and seafood, is associated with an increased risk of gout, whereas a higher level of consumption of dairy products is associated with a decreased risk [<a href="#rid64">64</a>]. Notably, however, the effects of genetic variation in urate-determining genes on circulating serum urate may exceed the effects of diet [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/105886.html" rel="external">"Nonpharmacologic strategies for the prevention and treatment of gout"</a>.) </p><p class="headingAnchor" id="H7"><span class="h1">HYPOURICEMIA</span><span class="headingEndMark"> — </span>Hypouricemia can be induced by decreased production (primarily due to rare enzyme defects) or increased urinary excretion. The latter can result from a genetic defect in the urate-organic anion exchanger URAT1 in the proximal tubule (encoded by the <em>SLC22A12</em> gene) [<a href="#rid14">14,66</a>], a loss-of-function genetic defect in the high-capacity renal urate transporter GLUT9 (encoded by <em>SLC2A9</em>) [<a href="#rid67">67</a>]. Thus, similar types of processes to those associated with hyperuricemia are involved in the pathogenesis of hypouricemia. (See  <a class="medical medical_review" href="/z/d/html/2315.html" rel="external">"Hypouricemia: Causes and clinical significance"</a>.)</p><p>Careful characterization of patients with severe hypouricemia due to homozygous loss-of-function alleles in <em>SLC2A9</em> provides important insight. These patients exhibit fractional excretions of urate that exceed 150 percent; since GLUT9 is the exclusive exit pathway for urate in reabsorption by the proximal tubule, renal urate reabsorption is abrogated completely and secretion predominates in these patients. Again, serum urate is to a large extent determined by the relative balance of urate reabsorption and secretion by the renal proximal tubule.</p><p class="headingAnchor" id="H68800977"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Uric acid is the end product of the metabolism of purine compounds. With a (functional) pKa of approximately 5.75 in blood (5.35 in urine), the reaction, uric acid  &lt;&gt; urate  +  H+, is shifted far to the right at the normal arterial pH of 7.40. As a result, most uric acid circulates as the urate anion. Normal humans have serum urate concentrations approaching the theoretical limit of solubility of urate in serum (6.8 mg/dL) and regularly excrete urine that is supersaturated with respect to uric acid. Normal adult males have a total body urate pool that averages approximately 1200 mg, nearly twice that of adult females. (See <a class="local">'Uric acid and urate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urate is produced in the liver from the degradation of dietary and endogenously synthesized purine compounds. Urate is not typically ingested, although dietary intake provides a significant source of urate precursors. Urate production involves the breakdown of the purine mononucleotides, guanylic acid (guanosine monophosphate, GMP), inosinic acid (inosine monophosphate, IMP), and adenylic acid (adenosine monophosphate, AMP), ultimately into the purine bases guanine and hypoxanthine. These last two compounds are then metabolized to xanthine, which is irreversibly oxidized by xanthine oxidase to produce urate  (<a class="graphic graphic_figure graphicRef75554" href="/z/d/graphic/75554.html" rel="external">figure 1</a>). (See <a class="local">'Urate production'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human tissues have a very limited ability to metabolize urate, which must be eliminated by the kidney and the gut to maintain homeostasis. Uric acid disposal by the kidney involves glomerular filtration of nearly all urate from the blood and tubular reabsorption and secretion mechanisms that normally result in net reabsorption of approximately 90 percent of the uric acid filtered at the glomerulus. The entry of urate into the intestine is mediated at least in part by the high-capacity urate efflux transporter, ABCG2, the product of the <em>ABCG2</em> gene, which is also expressed in proximal renal tubular epithelium. Intestinal tract bacteria degrade urate. This process (intestinal uricolysis) is responsible for approximately one-third of total urate disposal. Urinary uric acid excretion accounts for the remaining two-thirds of the daily uric acid disposal. (See <a class="local">'Uric acid disposal'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the renal proximal tubule, separate sets of transporters mediate urate reabsorption and urate secretion  (<a class="graphic graphic_figure graphicRef83926 graphicRef83925" href="/z/d/graphic/83926.html" rel="external">figure 2A-B</a>). Apical urate reabsorption by the proximal tubule has a secondary sodium dependency, with sodium-dependent uptake of "anti-uricosuric" anions driving apical urate-anion exchange via URAT1 and OAT10, followed by basolateral excretion via the GLUT9 urate transporter; these interactions explain the clinically relevant anti-uricosuric effects of pyrazinoate (PZA), nicotinate, and related anions. (See <a class="local">'Renal reabsorptive urate transport'</a> above and <a class="local">'Renal secretory urate transport'</a> above.)</p><p></p><p class="bulletIndent1">Urate homeostasis is regulated by multiple hormones, most prominently insulin, angiotensin, adrenaline, and parathyroid hormone. (See <a class="local">'Regulation of serum urate levels'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The relative balance of urate reabsorption and secretion by the proximal tubule determines renal excretion and thus circulating serum urate. Genetic variation in reabsorptive and secretory urate transporters and associated regulatory genes plays a major role in determining serum urate. (See <a class="local">'Regulation of serum urate levels'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased efficiency of renal uric acid excretion is responsible for most primary or secondary hyperuricemia  (<a class="graphic graphic_table graphicRef66799" href="/z/d/graphic/66799.html" rel="external">table 2</a>). This results from a reduced efficiency of urate excretion that obligates a higher serum urate concentration to achieve the necessary rate of urinary uric acid excretion. "Underexcretors" actually have normal rates of urinary uric acid excretion since this is required to maintain the steady state in which urate production and disposal are relatively equal. The remaining 10 to 15 percent of patients with hyperuricemia overexcrete uric acid in the daily urine; in some instances, this reflects inherited defects in regulation of purine nucleotide synthesis, disordered adenosine triphosphate (ATP) metabolism, or disorders resulting in increased rates of cell turnover. In other instances, overexcretion of urinary urate results from extra-renal urate underexcretion due to genetically determined defects in <em>ABCG2 </em>urate efflux into the gut. (See <a class="local">'Hyperuricemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypouricemia can be induced by decreased production (primarily due to rare enzyme defects) or to increased urinary excretion of uric acid. (See <a class="local">'Hypouricemia'</a> above.)</p><p></p><p class="headingAnchor" id="H338829217"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael A Becker, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mumford SL, Dasharathy SS, Pollack AZ, et al. Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study. Hum Reprod 2013; 28:1853.</a></li><li><a class="nounderline abstract_t">Döring A, Gieger C, Mehta D, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008; 40:430.</a></li><li><a class="nounderline abstract_t">Zeng M, Chen B, Qing Y, et al. Estrogen receptor β signaling induces autophagy and downregulates Glut9 expression. Nucleosides Nucleotides Nucleic Acids 2014; 33:455.</a></li><li><a class="nounderline abstract_t">Chen-Xu M, Yokose C, Rai SK, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol 2019; 71:991.</a></li><li><a class="nounderline abstract_t">Griebsch A, Zöllner N. Effect of ribomononucleotides given orally on uric acid production in man. Adv Exp Med Biol 1974; 41:443.</a></li><li><a class="nounderline abstract_t">Madeo A, Di Rocco M, Brassier A, et al. Clinical, biochemical and genetic characteristics of a cohort of 101 French and Italian patients with HPRT deficiency. Mol Genet Metab 2019; 127:147.</a></li><li><a class="nounderline abstract_t">Ahmed M, Taylor W, Smith PR, Becker MA. Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase. J Biol Chem 1999; 274:7482.</a></li><li><a class="nounderline abstract_t">Üsküdar Cansu D, Erdoğan B, Korkmaz C. Can hyperuricemia predict glycogen storage disease (McArdle's disease) in rheumatology practice? (Myogenic hyperuricemia). Clin Rheumatol 2019; 38:2941.</a></li><li><a class="nounderline abstract_t">Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 2009; 1:5ra11.</a></li><li><a class="nounderline abstract_t">Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012; 3:764.</a></li><li><a class="nounderline abstract_t">Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol 2015; 77:323.</a></li><li><a class="nounderline abstract_t">Huls M, Brown CD, Windass AS, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2008; 73:220.</a></li><li><a class="nounderline abstract_t">Sorensen LB. The elimination of uric acid in man. Scand J Clin Lab Invest 1960; 12 (supplement 54):1.</a></li><li><a class="nounderline abstract_t">Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447.</a></li><li><a class="nounderline abstract_t">Mandal AK, Mercado A, Foster A, et al. Uricosuric targets of tranilast. Pharmacol Res Perspect 2017; 5:e00291.</a></li><li><a class="nounderline abstract_t">Bahn A, Hagos Y, Reuter S, et al. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 2008; 283:16332.</a></li><li><a class="nounderline abstract_t">Tan PK, Liu S, Gunic E, Miner JN. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep 2017; 7:665.</a></li><li><a class="nounderline abstract_t">Miner JN, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther 2016; 18:214.</a></li><li><a class="nounderline abstract_t">Roch-Ramel F, Guisan B, Schild L. Indirect coupling of urate and p-aminohippurate transport to sodium in human brush-border membrane vesicles. Am J Physiol 1996; 270:F61.</a></li><li><a class="nounderline abstract_t">Guggino SE, Aronson PS. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. J Clin Invest 1985; 76:543.</a></li><li><a class="nounderline abstract_t">Goldfinger S, Klinenberg E Jr, Seegmiller JE. Renal retention of uric acid induced by infusion of beta-hydroxybutyrate and acetoacetate. N Engl J Med 1965; 272:351.</a></li><li><a class="nounderline abstract_t">Padova J, Bendersky G. Hyperuricemia in diabetic ketoacidosis. N Engl J Med 1962; 267:530.</a></li><li><a class="nounderline abstract_t">Harding VJ, Allin KD, Eagles BA. Influence of fat and carbohydrate diets upon the level of blood uric acid. J Biol Chem 1927; 74:631.</a></li><li><a class="nounderline abstract_t">Drenick EJ. Hyperuricemia, acute gout, renal insufficiency and urate nephrolithiasis due to starvation. Arthritis Rheum 1965; 8:988.</a></li><li><a class="nounderline abstract_t">Lieber CS, Jones DP, Losowsky MS, Davidson CS. Interrelation of uric acid and ethanol metabolism in man. J Clin Invest 1962; 41:1863.</a></li><li><a class="nounderline abstract_t">Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363:1277.</a></li><li><a class="nounderline abstract_t">Gibson HV, Doisy EA. A note on the effect of some organic acids upon the uric acid excretion of man. J Biol Chem 1923; 55:605.</a></li><li><a class="nounderline abstract_t">Michael ST. The relation of uric acid excretion to blood lactic acid in man. Am J Physiol 1944; 141:71.</a></li><li><a class="nounderline abstract_t">Gershon SL, Fox IH. Pharmacologic effects of nicotinic acid on human purine metabolism. J Lab Clin Med 1974; 84:179.</a></li><li><a class="nounderline abstract_t">Shapiro M, Hyde L. Hyperuricemia due to pyrazinamide. Am J Med 1957; 23:596.</a></li><li><a class="nounderline abstract_t">Roch-Ramel F, Guisan B. Renal Transport of Urate in Humans. News Physiol Sci 1999; 14:80.</a></li><li><a class="nounderline abstract_t">Iwanaga T, Sato M, Maeda T, et al. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320:211.</a></li><li><a class="nounderline abstract_t">Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010; 49:89.</a></li><li><a class="nounderline abstract_t">Iwanaga T, Kobayashi D, Hirayama M, et al. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 2005; 33:1791.</a></li><li><a class="nounderline abstract_t">Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40:437.</a></li><li><a class="nounderline abstract_t">Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283:26834.</a></li><li><a class="nounderline abstract_t">Witkowska K, Smith KM, Yao SY, et al. Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. Am J Physiol Renal Physiol 2012; 303:F527.</a></li><li><a class="nounderline abstract_t">Aslamkhan A, Han YH, Walden R, et al. Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am J Physiol Renal Physiol 2003; 285:F775.</a></li><li><a class="nounderline abstract_t">Bakhiya A, Bahn A, Burckhardt G, Wolff N. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 2003; 13:249.</a></li><li><a class="nounderline abstract_t">Sato M, Mamada H, Anzai N, et al. Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. Biol Pharm Bull 2010; 33:498.</a></li><li><a class="nounderline abstract_t">Uchino H, Tamai I, Yamashita K, et al. p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 2000; 270:254.</a></li><li><a class="nounderline abstract_t">Jutabha P, Anzai N, Kitamura K, et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem 2010; 285:35123.</a></li><li><a class="nounderline abstract_t">Masugi F, Ogihara T, Hashizume K, et al. Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension. J Hum Hypertens 1988; 1:293.</a></li><li><a class="nounderline abstract_t">Moriwaki Y, Yamamoto T, Tsutsumi Z, et al. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol. Metabolism 2002; 51:893.</a></li><li><a class="nounderline abstract_t">Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis 2006; 65:981.</a></li><li><a class="nounderline abstract_t">Beck LH. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1979; 301:528.</a></li><li><a class="nounderline abstract_t">Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442.</a></li><li><a class="nounderline abstract_t">Perez-Ruiz F, Aniel-Quiroga MA, Herrero-Beites AM, et al. Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. Rheumatol Int 2015; 35:1519.</a></li><li><a class="nounderline abstract_t">Quiñones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995; 268:E1.</a></li><li><a class="nounderline abstract_t">Ter Maaten JC, Voorburg A, Heine RJ, et al. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 1997; 92:51.</a></li><li><a class="nounderline abstract_t">Mandal AK, Leask MP, Estiverne C, et al. Genetic and Physiological Effects of Insulin on Human Urate Homeostasis. Front Physiol 2021; 12:713710.</a></li><li><a class="nounderline abstract_t">Christensson T. Serum urate in subjects with hypercalcaemic hyperparathyroidism. Clin Chim Acta 1977; 80:529.</a></li><li><a class="nounderline abstract_t">Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434.</a></li><li><a class="nounderline abstract_t">Ayvazian JH, Ayvazian IF. Changes in serum and urinary uric acid with the development of symptomatic gout. J Clin Invest 1963; 42:1835.</a></li><li><a class="nounderline abstract_t">Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 2002; 29:1950.</a></li><li class="breakAll">Wyngaarden JB, Kelley WN. Gout and Hyperuricemia, Grune and Stratton, New York 1976.</li><li><a class="nounderline abstract_t">Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47:610.</a></li><li><a class="nounderline abstract_t">Hoque KM, Dixon EE, Lewis RM, et al. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. Nat Commun 2020; 11:2767.</a></li><li><a class="nounderline abstract_t">Ketharnathan S, Leask M, Boocock J, et al. A non-coding genetic variant maximally associated with serum urate levels is functionally linked to HNF4A-dependent PDZK1 expression. Hum Mol Genet 2018; 27:3964.</a></li><li><a class="nounderline abstract_t">Boocock J, Leask M, Okada Y, et al. Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control. Hum Mol Genet 2020; 29:923.</a></li><li><a class="nounderline abstract_t">Tin A, Marten J, Halperin Kuhns VL, et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat Genet 2019; 51:1459.</a></li><li><a class="nounderline abstract_t">Urano W, Taniguchi A, Anzai N, et al. Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis 2010; 69:1232.</a></li><li><a class="nounderline abstract_t">Tanner C, Boocock J, Stahl EA, et al. Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men. Arthritis Rheumatol 2017; 69:1461.</a></li><li><a class="nounderline abstract_t">Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350:1093.</a></li><li><a class="nounderline abstract_t">Major TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ 2018; 363:k3951.</a></li><li><a class="nounderline abstract_t">Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15:164.</a></li><li><a class="nounderline abstract_t">Matsuo H, Chiba T, Nagamori S, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 2008; 83:744.</a></li></ol></div><div id="topicVersionRevision">Topic 1670 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23562957" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Serum uric acid in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18327256" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24972010" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Estrogen receptorβsignaling induces autophagy and downregulates Glut9 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30618180" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4832569" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of ribomononucleotides given orally on uric acid production in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31182398" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical, biochemical and genetic characteristics of a cohort of 101 French and Italian patients with HPRT deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10066814" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31044384" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Can hyperuricemia predict glycogen storage disease (McArdle's disease) in rheumatology practice? (Myogenic hyperuricemia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368174" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473008" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Decreased extra-renal urate excretion is a common cause of hyperuricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422986" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The molecular physiology of uric acid homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17978814" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The elimination of uric acid in man</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12024214" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Molecular identification of a renal urate anion exchanger that regulates blood urate levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28357121" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Uricosuric targets of tranilast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18411268" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28386072" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27716403" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8769823" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Indirect coupling of urate and p-aminohippurate transport to sodium in human brush-border membrane vesicles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4031062" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14239117" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Renal retention of uric acid induced by infusion of beta-hydroxybutyrate and acetoacetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14483098" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hyperuricemia in diabetic ketoacidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Influence of fat and carbohydrate diets upon the level of blood uric acid</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5863113" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hyperuricemia, acute gout, renal insufficiency and urate nephrolithiasis due to starvation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13930523" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interrelation of uric acid and ethanol metabolism in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15094272" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Alcohol intake and risk of incident gout in men: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A note on the effect of some organic acids upon the uric acid excretion of man</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The relation of uric acid excretion to blood lactic acid in man</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4367231" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pharmacologic effects of nicotinic acid on human purine metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13469830" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hyperuricemia due to pyrazinamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11390825" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Renal Transport of Urate in Humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043154" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075570" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of fenofibrate on uric acid metabolism and urate transporter 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135657" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18327257" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18701466" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22647630" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12837685" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14586168" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20190416" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10733936" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20810651" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3221377" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077737" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837492" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gout, diuretics and the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/460306" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17466656" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence of the metabolic syndrome in individuals with hyperuricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25763991" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840165" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of insulin on uric acid excretion in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9038591" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34408667" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Genetic and Physiological Effects of Insulin on Human Urate Homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/912919" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Serum urate in subjects with hypercalcaemic hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11346808" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14083171" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Changes in serum and urinary uric acid with the development of symptomatic gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233891" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233891" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522834" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32488095" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30124855" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A non-coding genetic variant maximally associated with serum urate levels is functionally linked to HNF4A-dependent PDZK1 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985003" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31578528" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556210" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28371506" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Population-Specific Resequencing Associates the ATP-Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15014182" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Purine-rich foods, dairy and protein intake, and the risk of gout in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30305269" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694169" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026395" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
